Banfi G, Ardemagni A, Bravi S, Pacchioni M, Bonini P
Servizio Intergrato di Medicina di Laboratorio, Istituto Scientifico H San Raffaele, Milano, Italy.
Int J Biol Markers. 1996 Oct-Dec;11(4):207-10. doi: 10.1177/172460089601100405.
Diabetes has been claimed to be a risk factor for pancreatic carcinoma, but it is probably a consequence of gland invasion from the neoplastic tissue. A link between diabetes and pancreatic carcinoma was suggested by means of biochemical markers of the diseases, namely glycated hemoglobin and CA19.9. Moreover, CA19.9 was proposed as a sensitive and useful marker of the severity of exocrine damage in diabetes, since the mucin decreased when metabolic compensation improved. We examined 64 diabetic patients (36 insulin dependent, 16 non insulin dependent, 12 treated with diet) by measuring CA19.9 using two different immunometric methods and glycemia and glycated hemoglobin. We observed that a correlation between CA19.9 and biochemical markers of metabolic compensation of diabetes was inexistent and no differences between insulin dependent and non insulin dependent patients were found. A high concentration of CA19.9 in a diabetic patient should be interpreted and evaluated in the same manner as for a non diabetic patient.
糖尿病被认为是胰腺癌的一个危险因素，但它可能是肿瘤组织侵犯腺体的结果。通过疾病的生化标志物，即糖化血红蛋白和CA19.9，提示了糖尿病与胰腺癌之间的联系。此外，CA19.9被认为是糖尿病外分泌损伤严重程度的一个敏感且有用的标志物，因为当代谢代偿改善时，粘蛋白会减少。我们通过两种不同的免疫测定方法测量CA19.9以及血糖和糖化血红蛋白，对64例糖尿病患者（36例胰岛素依赖型、16例非胰岛素依赖型、12例饮食治疗）进行了检查。我们观察到，CA19.9与糖尿病代谢代偿的生化标志物之间不存在相关性，胰岛素依赖型和非胰岛素依赖型患者之间也未发现差异。糖尿病患者中CA19.9浓度高的情况，应与非糖尿病患者一样进行解释和评估。
